ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/SA/5037-Kurralta-Park-Icon-Cancer-Centre-Adelaide
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
28
trial(s) found.
NCT07711184
Advanced
Phase 1
Recruiting
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-7525 Tablets in Patients With Advanced Prostate Cancer (
HRS-7525-101
)
unknown drug class
NOT Prostate neuroendocrine carcinoma
NOT Prostate small cell carcinoma
Prostate adenocarcinoma
Prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3121 - Richmond - Epworth Freemasons Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT07659795
Advanced
Phase 2
Recruiting
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203) (
TARGET-D-203
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
Colorectal adenocarcinoma
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT07644559
Advanced
Phase 2
Recruiting
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201) (
VS-7375-201
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
anti-EGFR monoclonal antibody
Pancreatic adenocarcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT07619287
Haem
Phase 1
Recruiting
A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BG-75202, Alone and in Combination With Other Agents, in Patients With Myeloid Malignancies (
BG-75202-102
)
KAT6A/B inhibitor
Myeloid leukaemia
NOT Solid tumour
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT07334119
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors (
MTX-HER2-304
)
CAR-NK/myeloid-cell therapy,ERBB2-targeting
HER2-expressing solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Linear Clinical Research
NCT07284849
Advanced
Phase 3
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer (
INCA033890-303
)
anti-VEGF monoclonal antibody
bispecific TGFBR2/PD-1 antibody
Colorectal adenocarcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2500 - Wollongong - Wollongong Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07225946
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-engaging Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer (
KLK2-PASenger
)
bispecific T-cell engager,KLK2-targeting
taxane
Castrate-resistant prostate cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Warringal Private Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT07218809
Advanced
Phase 3
Recruiting
A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (
TREVI-OC-01
)
anti-FR-alpha antibody-drug conjugate
Epithelial Ovarian Cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2487 - Cudgen - Tweed Valley Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT07164443
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Engaging Agent Targeting Human Kallikrein 2, With or Without JNJ-87189401, a PSMA-CD28 Costimulatory Agent, Plus Best Supportive Care Versus Best Supportive Care for Late-line Metastatic Castration-resistant Prostate Cancer (
KLK2-comPAS
)
bispecific PSMA/CD28 antibody
bispecific T-cell engager,KLK2-targeting
placebo
Castrate-resistant prostate cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Warringal Private Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07062965
Advanced
Phase 3
Recruiting
An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy (
C4551002
)
KAT6A/B inhibitor
KAT6 inhibitor
selective estrogen receptor degrader
Breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT07028853
Advanced
Phase 3
Recruiting
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3) (
C2321008
)
EZH2 inhibitor
antiandrogen,nonsteroidal,second generation
placebo
Castrate-sensitive prostate cancer
Prostate cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
QLD
4032 - Chermside - Icon Cancer Care Chermside
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT07011719
Advanced
Phase 3
Recruiting
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma (
PEAK-1
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
HIF2a inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
placebo
Clear cell renal cell carcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2086 - Frenchs Forest - Northern Beaches Hospital
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4032 - Chermside - Icon Cancer Care Chermside
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
TAS
7000 - Hobart - ICON Cancer Care Hobart
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3010 - Rotorua - Rotorua Hospital
NZ.3210 - Hamilton - Waikato Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06989437
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma (
C3651021
)
anti-GDF15 monoclonal antibody
placebo
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2541 - Nowra - Shoalhaven District Memorial Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06890598
Curative
Phase 3
Recruiting
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer -
SUNRAY-02
KRAS G12C inhibitor,OFF-state inhibitor
placebo
Non-small cell lung cancer
NSW
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3630 - Shepparton - Goulburn Valley Health
3844 - Traralgon - Latrobe Regional Hospital
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06764485
Advanced
Phase 3
Recruiting
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) -
rechARge
dual AR degrader antagonist
taxane
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2076 - Wahroonga - Sydney Adventist Hospital
2109 - North Ryde - Macquarie University Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2560 - Campbelltown - GenesisCare Campbelltown
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06712355
Advanced
Phase 3
Recruiting
A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer (
BNT327-03
)
anti-PD-L1 monoclonal antibody
bispecific PD-L1/VEGFA antibody
platinum-based antineoplastic agent
topoisomerase inhibitor
Small-cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Cancer Care Wollongong
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4870 - Cairns - Cairns Base Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06712316
Advanced
Phase 2 / Phase 3
Recruiting
A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer (
BNT327-06
)
bispecific PD-L1/VEGFA antibody
Non-small cell lung cancer
NSW
2500 - Wollongong - Cancer Care Wollongong
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
2830 - Dubbo - Dubbo Base Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4812 - Hyde Park - Icon Cancer Centre Townsville
4870 - Cairns - Cairns Base Hospital
SA
5000 - Adelaide - Cancer Research SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
NCT06588478
Haem
Phase 2
Recruiting
A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor
BTK inhibitor
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2200 - Bankstown - Bankstown-Lidcombe Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3844 - Traralgon - Latrobe Regional Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6005 - West Perth - Perth Blood Institute
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06533332
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1 Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of Escalating Doses of ERX-315 in Participants With Advanced Solid Tumors (
ERX-315-101
)
benzamide,ER alpha-targeting
Breast cancer
Endometrial cancer
Hepatocellular carcinoma
Ovarian cancer
Pancreatic cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
SA
5000 - Adelaide - Cancer Research SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06492616
Curative
Phase 3
Recruiting
Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study (
ELEGANT
)
selective estrogen receptor degrader
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2060 - North Sydney - Mater Hospital
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2480 - Lismore - Lismore Base Hospital
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3135 - Ringwood East - Maroondah Hospital
3168 - Clayton - Monash Medical Centre
3630 - Shepparton - Goulburn Valley Health
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4215 - Southport - ICON Cancer Care
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5000 - Adelaide - Cancer Research SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - ICON Cancer Care Hobart
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NCT06244771
Advanced
Phase 1 / Phase 2
Recruiting
An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors (
PROSPER
)
KRAS G12C inhibitor,ON/OFF-state inhibitor
Colorectal cancer
Non-small cell lung cancer
Pancreatic cancer
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Tasman Oncology
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Linear Clinical Research
NA
NA
NCT06242470
Advanced
Phase 1
Recruiting
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors (
CP-MGC026-01
)
anti-B7H3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Bladder cancer
Breast cancer
Castrate-resistant prostate cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Platinum resistant ovarian cancer
Prostate adenocarcinoma
Sarcoma
Small-cell lung cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT05981703
Advanced
Phase 1
Recruiting
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors (
BGB-A317-26808-101
)
HPK1 inhibitor
anti-PD-1 monoclonal antibody
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2228 - Miranda - Southside Cancer Care Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3010 - Rotorua - Rotorua Hospital
NCT05868174
Radonc
Phase 1
Recruiting
A Phase 1b Dose Escalation/Expansion Study of the Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX (CAIX)-Expressing Solid Tumors (
177Lu-TLX250-001
)
DNA-dependent protein kinase inhibitor
radioconjugate,CA9-targeting
Clear cell renal cell carcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05818683
Advanced
Phase 1
Recruiting
A Phase 1b Study of JNJ-78278343, Targeting Human Kallikrein 2 (KLK2) in Combination With Other Agents for Metastatic Prostate Cancer (
CR109321
)
bispecific T-cell engager,KLK2-targeting
Castrate-resistant prostate cancer
Castrate-sensitive prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT05393791
Advanced
Phase 2
Recruiting
ANZadapt
: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer
CYP17A1 inhibitor
antiandrogen,nonsteroidal,second generation
Castrate-resistant prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05128825
Advanced
Phase 2
Recruiting
A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (
DENALI
/ ZN-c3-005 / GOG-3066)
WEE1 inhibitor
High-grade serous ovarian cancer
Ovarian cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4032 - Chermside - Icon Cancer Care Chermside
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5065 - Toorak Gardens - Burnside War Memorial Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04176198
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis (
BBI-TP-3654-102
)
PIM1 kinase inhibitor,selective
Myelofibrosis
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (28)
Recruitment Country and State
SA (28)
NSW (22)
QLD (22)
VIC (22)
WA (16)
TAS (5)
NZ (4)
ACT (2)
Phase
Phase 1 (8)
Phase 1 / Phase 2 (2)
Phase 2 (5)
Phase 2 / Phase 3 (2)
Phase 3 (11)
Trial Type
Advanced (22)
Haem (3)
Curative (2)
Radonc (1)
Cancer Therapy Class
PD-1/PD-L1
25%
PD-1
21%
KRAS
14%
AR
14%
androgen axis
14%
KLK2
11%
oestrogen axis
11%
PD-L1
11%
CYP17A1
11%
EGFR
7%
KAT6A
7%
ER
7%
VEGFA
7%
ERBB2
4%
TGFBR2
4%
VEGF
4%
FR-alpha
4%
KAT6
4%
mTOR
4%
mTORC1
4%
EZH2
4%
AXL
4%
HIF2a
4%
KIT
4%
MET
4%
RET
4%
ROS1
4%
VEGFR
4%
VEGFR2
4%
GDF15
4%
AR
4%
BTK
4%
ER alpha
4%
B7H3
4%
HPK1
4%
DNA-dependent protein kinase
4%
PSMA
4%
WEE1
4%
JAK1
4%
JAK2
4%
Facility
5037 - Kurralta Park - Icon Cancer Centre Adelaide (28)
2109 - North Ryde - Macquarie University Hospital (10)
3000 - Melbourne - Peter MacCallum Cancer Centre (9)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (9)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (8)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (7)
3128 - Box Hill - Box Hill Hospital - Eastern Health (7)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (6)
4102 - Woolloongabba - Princess Alexandra Hospital (6)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (5)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (5)
6150 - Murdoch - Fiona Stanley Hospital (5)
3021 - St Albans - Western Health - Sunshine Hospital (5)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (5)
2217 - Kogarah - St George Hospital (4)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (4)
2076 - Wahroonga - Sydney Adventist Hospital (4)
3168 - Clayton - Monash Medical Centre (4)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (4)
7000 - Hobart - ICON Cancer Care Hobart (4)
3121 - Richmond - Epworth Freemasons Hospital (3)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (3)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (3)
4032 - Chermside - Icon Cancer Care Chermside (3)
3199 - Frankston - Peninsula Health Frankston Hospital (3)
5000 - Adelaide - Cancer Research SA (3)
5042 - Bedford Park - Flinders Medical Centre (3)
6009 - Nedlands - Linear Clinical Research (2)
2605 - Garran - The Canberra Hospital (2)
3004 - Melbourne, Southbank - Alfred Health (2)
3084 - Heidelberg - Warringal Private Hospital (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (2)
NZ.3210 - Hamilton - Waikato Hospital (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
5112 - Elizabeth Vale - Lyell McEwin Hospital (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
NZ.3010 - Rotorua - Rotorua Hospital (2)
3630 - Shepparton - Goulburn Valley Health (2)
3844 - Traralgon - Latrobe Regional Hospital (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
4215 - Southport - Tasman Oncology (2)
2500 - Wollongong - Cancer Care Wollongong (2)
4870 - Cairns - Cairns Base Hospital (2)
5011 - Woodville South - The Queen Elizabeth Hospital (2)
4812 - Hyde Park - Icon Cancer Centre Townsville (2)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital (1)
2031 - Randwick - Prince of Wales Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2487 - Cudgen - Tweed Valley Hospital (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
2086 - Frenchs Forest - Northern Beaches Hospital (1)
2541 - Nowra - Shoalhaven District Memorial Hospital (1)
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (1)
2560 - Campbelltown - GenesisCare Campbelltown (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
2830 - Dubbo - Dubbo Base Hospital (1)
2200 - Bankstown - Bankstown-Lidcombe Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
6005 - West Perth - Perth Blood Institute (1)
7000 - Hobart - Royal Hobart Hospital (1)
2060 - North Sydney - Mater Hospital (1)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (1)
2480 - Lismore - Lismore Base Hospital (1)
3066 - Epping - Northern Hospital (1)
3135 - Ringwood East - Maroondah Hospital (1)
4215 - Southport - ICON Cancer Care (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
NA
2228 - Miranda - Southside Cancer Care Centre (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
3002 - East Melbourne - Epworth Freemasons (1)
5065 - Toorak Gardens - Burnside War Memorial Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
Cancer Type
Cancer
Solid tumour
Urogenital cancer
Male genital cancers
Prostate adenocarcinoma
Prostate cancer
Gastrointestinal cancer
Castrate-resistant prostate cancer
Pancreatic cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Lung cancer
Respiratory tract cancer
Thoracic cancer
Colorectal cancer
Lower gastrointestinal cancer
Gynaecological cancer
Ovarian cancer
Breast cancer
Non-small cell lung cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Haematological malignancy
Epithelial Ovarian Cancer
Clear cell renal cell carcinoma
Kidney cancer
Colorectal adenocarcinoma
Leukaemia
Castrate-sensitive prostate cancer
Carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Endometrial cancer
Hepatobiliary cancer
Hepatocellular carcinoma
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
High-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian serous carcinoma
Myeloid leukaemia
HER2-expressing solid tumour
HER2-positive solid tumour
B-cell lymphoma
B-cell malignancy
Chronic lymphocytic leukaemia
Lymphoid leukaemia
Lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Small lymphocytic lymphoma
Bladder cancer
Cervical cancer
Gastric cancer
Gastroesophageal cancer
HPV-related cancer
HPV16-positive cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Melanoma
Oesophageal cancer
Platinum resistant ovarian cancer
Sarcoma
Viral-related cancer
Fallopian tube cancer
Peritoneal cancer
Primary fallopian tube serous carcinoma
Primary peritoneal serous carcinoma
Myelofibrosis
Myeloproliferative neoplasm
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy